TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00630487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Fixed doses for patients: MALE: \< 45y 0,4 mg, \> 45y 0,2mg FEMALE: \< 45y 0,5mg, \>45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
Study: NCT03102853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nordic diet

Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Study: NCT01030952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nateglinide
Description: Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
Study: NCT01102504

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ateronon
Description: Tomato extract containing 28 mg lycopene/ day
Study: NCT03706105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation
Description: 3 x week \~1 hour of exercise + education
Study: NCT01084473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
Study: NCT01030952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
Study: NCT01454505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-53817 nasal spray solution
Description: Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle nasal spray
Description: Inactive ingredients used as placebo comparator during Stage A and Stage B.
Study: NCT04322435

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous blood glucose measurement
Description: Continuous blood glucose measurement with Abbott Freestyle Pro for 14 days, repeated twice at 6 months intervals.

Intervention type: OTHER
Group type: OTHER
Intervention: Measurement of capillary blood glucose
Description: Measurement of capillary blood glucose :~* In the morning on an empty stomach, every first week of each month for 12 months.~* In case of suspicion of hypoglycaemia (parental assessment). Abbott's Freestyle optium neo reader, used with the Accu-Chek FastClix lancing device and the Accu-Chek Performa strips.
Study: NCT05242068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinlite
Description: Use of vein imaging device for visualization of veins during peripheral IV placement

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: Patients received standard intravenous catheterization.
Study: NCT04736290

Intervention type: OTHER
Intervention: NLR
Description: Calculation of NLR

Intervention type: OTHER
Intervention: PLR
Description: Calculation of PLR
Study: NCT03544424

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01084473

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % NaCl will be infused.
Study: NCT01732510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8226
Description: MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
Study: NCT03181334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Branch I
Description: FIT kits and a Standard (control) invitation letter to complete CRC screening is mailed to the homes of eligible patients.
Study: NCT01922986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: 10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
Study: NCT03181334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch II
Description: FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch II: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week.
Study: NCT01732510

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV every 2 weeks for a period of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV every 2 weeks for a period of 12 weeks.
Study: NCT01582516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: delta-24-RGD adenovirus
Description: slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
Study: NCT03181334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch III
Description: FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch IV
Description: FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch V
Description: FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive.
Study: NCT00895167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: one oral dose of 12 caplets = 12 g curcumin
Study: NCT00601458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
Study: NCT01922986

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: 20 minutes of sham rTMS stimulation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional stroke therapy
Description: conventional stroke therapy consisting of exercises and physical training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional stroke therapy
Description: conventional stroke therapy consisting of exercises and physical training
Study: NCT02302586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Description: Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (IV PCA)
Description: IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
Study: NCT02778542

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Pill Bottle
Description: Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bidirectional Text Messaging
Description: Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
Study: NCT01469936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PERMEAPROTECT
Description: Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day
Study: NCT03071315

Intervention type: OTHER
Intervention: CCT
Description: CCT focuses on behavioral approach, mainly punitive punishment measures.

Intervention type: OTHER
Intervention: MMT
Description: MMT is a combination of pharmaceutical and behavioral intervention.
Study: NCT00989846

Intervention type: OTHER
Intervention: biomarker
Description: measuring serum-biomarkers
Study: NCT03774043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia
Description: Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia
Description: Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
Study: NCT02922816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bowel preparation
Description: Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Description: Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
Study: NCT05152992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing visual stimuli and electrical stimulation of the brain
Description: View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
Study: NCT00130546

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting TAXUS(TM)
Description: TAXUS(TM) Paclitaxel-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting Cypher Select(TM)
Description: Sirolimus eluting Cypher Select(TM) stent
Study: NCT01087359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study: NCT02922816

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stool or perirectal swab sampling
Description: Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stool or perirectal swab sampling
Description: Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
Study: NCT06531187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Practice (EBP) Teaching
Description: The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Practice (EBP) Teaching
Description: The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP).
Study: NCT01814046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young Tumor Infiltrating Lymphocytes (TIL)
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study: NCT00601458

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Study: NCT01815515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFBC
Description: 18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
Study: NCT01814046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young Tumor Infiltrating Lymphocytes (TIL)
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study: NCT01218568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin plus lactulose
Description: Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 30-60 ml in two or three divided doses.
Study: NCT00380497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Lyte®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pico-Salax®
Study: NCT03406572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFHO Group
Description: * Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard O2
Description: Standard oxygen therapy
Study: NCT02670837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellutome Epidermal Harvesting System
Study: NCT04023344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix25
Description: Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Biphasic 25
Description: Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study: NCT01866306

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
Study: NCT05349994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended physiotherapy
Description: At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
Study: NCT01200602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: No treatment is given.
Study: NCT03984097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneously.